Dr. Brian I. Rini from the Taussig Cancer Institute Explains the Axitinib Integration Process
OncLive TV
Dr. Tim J. Whelan from Juravinski Cancer Centre on the Percentage the MA.20 Trial Benefits
Advertisement
Dr. Timothy J. Whelan from Juravinski Cancer Centre Discusses the MA.20 Trial's Survival Findings
Dr. Allen S. Lichter Chief Executive Officer (CEO) of the American Society of Clinical Oncology on ASCO's Global Collaboration Focus
Dr. Mark G. Kris from Memorial Sloan-Kettering on Integrating Driver Mutation Testing Study Results
Dr. H. Jack West from Swedish Cancer Institute discusses Afatinib and Cetuximab Combination in NSCLC
Advertisement
Dr. Axel Hoos from Bristol Myers-Squibb on Tools Available to Measure Ipilimumab's Success
Dr. Lynn M. Schuchter from Penn Med on the Next Steps in Melanoma Research
Dr. Brian I. Rini from the Taussig Cancer Institute Describes Axitinib's and Sorafenib's Side Effects
Dr. David Cella from Northwestern University Feinberg School of Medicine on the Value of Patient-Reported Outcomes
Dr. Heikki Joensuu from the Helsinki University Central Hospital Discusses Resistance to Imatinib in GIST
Dr. Mark G. Kris from memorial sloan-kettering Talks About the importance of Defining the broad term Biomarkers
Dr. Brian Rini from Taussig Cancer Institute explains the Axitinib and Sorafenib AXIS Trial VEGF Potency Focus
Dr. Axel Hoos the medical lead in Immunology/Oncology at Bristol-Myers Squibb Discusses the Clinical Kinetics of Immunotherapy
Dr. Mark Kris from MSKCC Describes the Genetic Mutation Screening Multicenter Study
Dr. H. Jack West from Swedish Cancer Institute Discusses ALK-NSCLC Crizotinib Survival Benefit
Dr. Lynn Schuchter chief of Hematology Oncology at Penn Medicine Reserves BRAF Testing for Advanced Melanoma
Dr. Howard Scher from MSKCC on Using the Circulating Tumor Cells Test
Dr. NJ Vogelzang from the Comprehensive Cancer Centers of Nevada Discusses Cabozantinib's Dose Size
Dr. David Cella from Northwestern University Feinberg School of Medicine on Quality of Life Assessments' Cost Effectiveness
Dr. Howard Scher from Memorial Sloan-Kettering on the Future of the Circulating Tumor Cell Test
Donna Berry on the Challenges Patients With Prostate Cancer Face
Dr. Kris from Memorial Sloan-Kettering Discusses Tests Available for Lung Cancer
Dr. Schuchter chief of Hematology Oncology at Penn Medicine on Testing for a BRAF Mutation in Melanoma
Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Axitinib and Sorafenib Trial Hazard Ratio
Dr. Howard Scher from Memorial Sloan-Kettering on Circulating Tumor Cells in Prostate Cancer
Dr. Brian Rini from the Cleveland Clinic Taussig Cancer Institute on the Results From His Axitinib and Sorafenib Trial
Dr. Sonali Smith director Lymphoma Program at the University of Chicago Medical Center Discusses Lymphoma in the Elderly
Dr. David Cella from Northwestern University Feinberg School of Medicine Explains the Increase in Quality of Life Assessments
Dr. Howard Scher form Memorial Sloan-Kettering Cancer Center Discusses Circulating Tumor Cells
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Novel Targeted Agents Are Poised to Influence the MPN Treatment Paradigm: With John O. Mascarenhas, MD
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Aligning Patient Goals and Toxicity Burden Are Key in First-Line Chemo Selection in Pancreatic Cancer
5